Literature DB >> 18489991

Similar risks for chronic kidney disease in long-term survivors of myeloablative and reduced-intensity allogeneic hematopoietic cell transplantation.

Ahmed Al-Hazzouri1, Qing Cao, Linda J Burns, Daniel J Weisdorf, Navneet S Majhail.   

Abstract

Chronic kidney disease (CKD) in recipients of myeloablative (MA) allogeneic hematopoietic cell transplantation (HCT) has been well characterized. However, the risk of CKD after HCT using reduced-intensity conditioning (RIC) is not well known. We compared the incidence of CKD by conditioning regimen in 221 allogeneic HCT recipients (MA = 117, RIC = 104) who had survived for >or=1 year post-HCT and had no history of CKD pretransplant. CKD was defined as glomerular filtration rate (GFR) <60 mL/min/1.73 m(2) for >or=3 months anytime after 180 days post-HCT. The median follow-up was 28 months (range: 12-75) for MA and 25 months (range: 12-67) for the RIC group. The 3-year cumulative incidence rate of CKD was 28% (95% confidence intervals [CI], 19%-36%) in MA and 29% (95% CI, 20%-38%) in the RIC group (P = .44). In multivariate analysis, conditioning regimen intensity had no impact on the risk of developing CKD (relative risk [RR] for MA 1.50 [95% CI, 0.78-2.89] versus the RIC regimen). Factors independently associated with an increased risk of CKD were older age at transplant, acute graft-versus-host disease, cyclosporine use for >6 months, and acute kidney injury in the early posttransplant period. CKD is frequent in long-term adult allogeneic HCT survivors, but RIC is associated with similar risks as MA conditioning. Continuous monitoring of renal function is necessary in allogeneic HCT survivors, and studies exploring prevention strategies are needed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18489991     DOI: 10.1016/j.bbmt.2008.03.008

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  6 in total

1.  Treatment with Foscarnet after Allogeneic Hematopoietic Cell Transplant (Allo-HCT) Is Associated with Long-Term Loss of Renal Function.

Authors:  Gena G Foster; Michael J Grant; Samantha M Thomas; Blake Cameron; Doug Raiff; Kelly Corbet; Gavin Loitsch; Christopher Ferreri; Mitchell Horwitz
Journal:  Biol Blood Marrow Transplant       Date:  2020-05-23       Impact factor: 5.742

Review 2.  Chronic kidney disease after hematopoietic stem cell transplantation.

Authors:  Eric P Cohen; Priya Pais; John E Moulder
Journal:  Semin Nephrol       Date:  2010-11       Impact factor: 5.299

3.  Chronic kidney disease, thrombotic microangiopathy, and hypertension following T cell-depleted hematopoietic stem cell transplantation.

Authors:  Ilya G Glezerman; Kenar D Jhaveri; Thomas H Watson; Alison M Edwards; Esperanza B Papadopoulos; James W Young; Carlos D Flombaum; Ann A Jakubowski
Journal:  Biol Blood Marrow Transplant       Date:  2010-02-12       Impact factor: 5.742

Review 4.  Long-Term Health Effects of Curative Therapies on Heart, Lungs, and Kidneys for Individuals with Sickle Cell Disease Compared to Those with Hematologic Malignancies.

Authors:  Courtney D Fitzhugh; Emmanuel J Volanakis; Ombeni Idassi; Josh A Duberman; Michael R DeBaun; Debra L Friedman
Journal:  J Clin Med       Date:  2022-05-31       Impact factor: 4.964

5.  Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update.

Authors:  B Mohty; M Mohty
Journal:  Blood Cancer J       Date:  2011-04-29       Impact factor: 11.037

6.  Long term renal survival in patients undergoing T-Cell depleted versus conventional hematopoietic stem cell transplants.

Authors:  I G Glezerman; S Devlin; M Maloy; M Bui; E A Jaimes; S A Giralt; A A Jakubowski
Journal:  Bone Marrow Transplant       Date:  2017-01-16       Impact factor: 5.483

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.